Novavax should be able to derive substantial revenue streams from those countries. In any case, the thrust of the idea is clear: the FDA doesn’t govern the company’s applications in those nations.
https://investorplace.com/2022/01/nvax-stock-continues-to-require-patience-but-it-should-pay-off/

